Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5367272 | 0.86 | ALDH1A1 (0.51) | PTPN1KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL3262155 | 0.81 | NPSR1 (0.45) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL11584039 | 0.80 | NPSR1 (0.47) | PTPN1KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL7026581 | 0.80 | GPR35 (0.61) | PTPN1KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL15842309 | 0.79 | HPGD (0.53) | PTPN1KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL11584435 | 0.75 | KDM4E (0.48) | PTPN1KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL5858393 | 0.73 | MAOB (0.57) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL5288407 | 0.73 | ALDH1A1 (0.60) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL11151090 | 0.70 | CA12 (0.56) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL29953425 | 0.70 | PTPN1 (0.49) | PTPN1KDM4EALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836142-B | 3-chromone-2-sulfonyl acrylonitrile derivative and preparation method and application thereof | 广东海洋大学 | 2023-12-12 | — | — | CN | claimed |
| CN-116836142-A | 3-chromone-2-sulfonyl acrylonitrile derivative and preparation method and application thereof | 广东海洋大学 | 2023-10-03 | — | — | CN | claimed |
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
| CN-116836142-B | 3-chromone-2-sulfonyl acrylonitrile derivative and preparation method and application thereof | 广东海洋大学 | 2023-12-12 | — | — | CN | disclosed |
| CN-116836142-A | 3-chromone-2-sulfonyl acrylonitrile derivative and preparation method and application thereof | 广东海洋大学 | 2023-10-03 | — | — | CN | disclosed |
| US-20120316192-A1 | SUBSTITUTED INDOLO [2,3-A] QUINOLIZINES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-12-13 | — | — | US | disclosed |
| EP-2532664-A1 | Substituted indolo [2,3-a] quinolizines in the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1322308-A2 | DEVICES AND METHODS FOR MANAGEMENT OF INFLAMMATION | Durect Corporation (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002028366-A2 | DEVICES AND METHODS FOR MANAGEMENT OF INFLAMMATION | DURECT CORPORATION (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-0843551-B1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000053313-A2 | LANTHANIDE CATALYSTS FOR SYNTHESIS OF COMPOUNDS AND COMBINATORIAL LIBRARIES | ARQULE, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| EP-0843551-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1998-08-12 | — | — | EP | disclosed |
| EP-0843551-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997004773-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316192-A1 | SUBSTITUTED INDOLO [2,3-A] QUINOLIZINES | BOD1L1, ACIN1, CDC25C | PTPN1 1437/4885KDM4E 2292/4885ALDH1A1 2785/4885 |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PTPN1 882/4885KDM4E 2527/4885ALDH1A1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.